Evaluating Endometriosis With 16α-(18)F-fluoro-17β-estradiol ([F-18] FES) PET/MRI
NCT ID: NCT04347135
Last Updated: 2024-05-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
PHASE1/PHASE2
INTERVENTIONAL
2022-10-07
2024-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluation of Endometriosis With 18F-fluoroestradiol PET / MRI
NCT04382911
Evaluation of Endometriosis With 18F-fluorofuranylnorprogesterone PET / MRI
NCT05480995
Assessment of Performance of [18F]-FES for Endometriosis Diagnosis
NCT02233621
PET/MRI for Evaluation of Endometriosis
NCT06377553
The Role of FAPI PET-CT in Diagnosing Endometriosis
NCT06792318
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
F-18 FES PET/MRI
16α-(18)F-fluoro-17β-estradiol (\[F-18\] FES)
F-18 FES
F-18 FES PET/MRI for detection of endometriosis.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
F-18 FES
F-18 FES PET/MRI for detection of endometriosis.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* AP diameter when lying supine greater than 32 cm (too large for PET/MRI)
* Unable to undergo PET/MRI for any reason (metal implants, severe claustrophobia)
* Unable to receive IV Gadolinium contrast for any reason (renal failure eGFR \< 60, contrast allergy)
* Pregnant (Urine test will be provided for all patients)
18 Years
50 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Annie (Annie) T. Packard
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Annie (Annie) T. Packard
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ann Packard, MD
Role: PRINCIPAL_INVESTIGATOR
Mayo Clinic
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Mayo Clinic in Rochester
Rochester, Minnesota, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Mayo Clinic Clinical Trials
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
19-004345
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.